Selected research
Industry Research
Herpes Labialis Drugs Industry Research Report 2026
Market perspective
The global Herpes Labialis Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Herpes Labialis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Herpes Labialis Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Herpes Labialis Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Herpes Labialis Drugs include GSK, Teva, Novartis, Mylan, Livzon, Bayer, Med Shine, Hikma and Daewoong Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Herpes Labialis Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Herpes Labialis Drugs Market by Company
GSK
Teva
Novartis
Mylan
Livzon
Bayer
Med Shine
Hikma
Daewoong Pharmaceutical
Cipher
Carmex
Cadila
Blistex
Apotex
Herpes Labialis Drugs Segment by Type
Aciclovir
Docosanol
Famciclovir
Valacyclovir
Other
Herpes Labialis Drugs Segment by Application
Injection
External Use
Oral
Herpes Labialis Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Herpes Labialis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Herpes Labialis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Herpes Labialis Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Herpes Labialis Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Herpes Labialis Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Herpes Labialis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Aciclovir
- Docosanol
- Famciclovir
- Valacyclovir
- Other
Applications
- Injection
- External Use
- Oral
Companies covered
- GSK
- Teva
- Novartis
- Mylan
- Livzon
- Bayer
- Med Shine
- Hikma
- Daewoong Pharmaceutical
- Cipher
- Carmex
- Cadila
- Blistex
- Apotex
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Herpes Labialis Drugs Market Size (2021-2032)
- 2.2.2 Global Herpes Labialis Drugs Sales (2021-2032)
- 2.2.3 Global Herpes Labialis Drugs Market Average Price (2021-2032)
- 2.3 Herpes Labialis Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Aciclovir
- 2.3.3 Docosanol
- 2.3.4 Famciclovir
- 2.3.5 Valacyclovir
- 2.3.6 Other
- 2.4 Herpes Labialis Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Injection
- 2.4.3 External Use
- 2.4.4 Oral
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Herpes Labialis Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Herpes Labialis Drugs Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Herpes Labialis Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Herpes Labialis Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Herpes Labialis Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Herpes Labialis Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Herpes Labialis Drugs, Product Type & Application
- 3.8 Global Manufacturers of Herpes Labialis Drugs, Established Date
- 3.9 Global Herpes Labialis Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 GSK
- 4.1.1 GSK Company Information
- 4.1.2 GSK Business Overview
- 4.1.3 GSK Herpes Labialis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 GSK Herpes Labialis Drugs Product Portfolio
- 4.1.5 GSK Recent Developments
- 4.2 Teva
- 4.2.1 Teva Company Information
- 4.2.2 Teva Business Overview
- 4.2.3 Teva Herpes Labialis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Teva Herpes Labialis Drugs Product Portfolio
- 4.2.5 Teva Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis Herpes Labialis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis Herpes Labialis Drugs Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 Mylan
- 4.4.1 Mylan Company Information
- 4.4.2 Mylan Business Overview
- 4.4.3 Mylan Herpes Labialis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Mylan Herpes Labialis Drugs Product Portfolio
- 4.4.5 Mylan Recent Developments
- 4.5 Livzon
- 4.5.1 Livzon Company Information
- 4.5.2 Livzon Business Overview
- 4.5.3 Livzon Herpes Labialis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Livzon Herpes Labialis Drugs Product Portfolio
- 4.5.5 Livzon Recent Developments
- 4.6 Bayer
- 4.6.1 Bayer Company Information
- 4.6.2 Bayer Business Overview
- 4.6.3 Bayer Herpes Labialis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bayer Herpes Labialis Drugs Product Portfolio
- 4.6.5 Bayer Recent Developments
- 4.7 Med Shine
- 4.7.1 Med Shine Company Information
- 4.7.2 Med Shine Business Overview
- 4.7.3 Med Shine Herpes Labialis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Med Shine Herpes Labialis Drugs Product Portfolio
- 4.7.5 Med Shine Recent Developments
- 4.8 Hikma
- 4.8.1 Hikma Company Information
- 4.8.2 Hikma Business Overview
- 4.8.3 Hikma Herpes Labialis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Hikma Herpes Labialis Drugs Product Portfolio
- 4.8.5 Hikma Recent Developments
- 4.9 Daewoong Pharmaceutical
- 4.9.1 Daewoong Pharmaceutical Company Information
- 4.9.2 Daewoong Pharmaceutical Business Overview
- 4.9.3 Daewoong Pharmaceutical Herpes Labialis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Daewoong Pharmaceutical Herpes Labialis Drugs Product Portfolio
- 4.9.5 Daewoong Pharmaceutical Recent Developments
- 4.10 Cipher
- 4.10.1 Cipher Company Information
- 4.10.2 Cipher Business Overview
- 4.10.3 Cipher Herpes Labialis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Cipher Herpes Labialis Drugs Product Portfolio
- 4.10.5 Cipher Recent Developments
- 4.11 Carmex
- 4.11.1 Carmex Company Information
- 4.11.2 Carmex Business Overview
- 4.11.3 Carmex Herpes Labialis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Carmex Herpes Labialis Drugs Product Portfolio
- 4.11.5 Carmex Recent Developments
- 4.12 Cadila
- 4.12.1 Cadila Company Information
- 4.12.2 Cadila Business Overview
- 4.12.3 Cadila Herpes Labialis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Cadila Herpes Labialis Drugs Product Portfolio
- 4.12.5 Cadila Recent Developments
- 4.13 Blistex
- 4.13.1 Blistex Company Information
- 4.13.2 Blistex Business Overview
- 4.13.3 Blistex Herpes Labialis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Blistex Herpes Labialis Drugs Product Portfolio
- 4.13.5 Blistex Recent Developments
- 4.14 Apotex
- 4.14.1 Apotex Company Information
- 4.14.2 Apotex Business Overview
- 4.14.3 Apotex Herpes Labialis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Apotex Herpes Labialis Drugs Product Portfolio
- 4.14.5 Apotex Recent Developments
5 Global Herpes Labialis Drugs Market Scenario by Region
- 5.1 Global Herpes Labialis Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Herpes Labialis Drugs Sales by Region: 2021-2032
- 5.2.1 Global Herpes Labialis Drugs Sales by Region: 2021-2026
- 5.2.2 Global Herpes Labialis Drugs Sales by Region: 2027-2032
- 5.3 Global Herpes Labialis Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Herpes Labialis Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Herpes Labialis Drugs Revenue by Region: 2027-2032
- 5.4 North America Herpes Labialis Drugs Market Facts & Figures by Country
- 5.4.1 North America Herpes Labialis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Herpes Labialis Drugs Sales by Country (2021-2032)
- 5.4.3 North America Herpes Labialis Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Herpes Labialis Drugs Market Facts & Figures by Country
- 5.5.1 Europe Herpes Labialis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Herpes Labialis Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Herpes Labialis Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Herpes Labialis Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Herpes Labialis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Herpes Labialis Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Herpes Labialis Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Herpes Labialis Drugs Market Facts & Figures by Country
- 5.7.1 South America Herpes Labialis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Herpes Labialis Drugs Sales by Country (2021-2032)
- 5.7.3 South America Herpes Labialis Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Herpes Labialis Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Herpes Labialis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Herpes Labialis Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Herpes Labialis Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Herpes Labialis Drugs Sales by Type (2021-2032)
- 6.1.1 Global Herpes Labialis Drugs Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Herpes Labialis Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Herpes Labialis Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Herpes Labialis Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Herpes Labialis Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Herpes Labialis Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Herpes Labialis Drugs Sales by Application (2021-2032)
- 7.1.1 Global Herpes Labialis Drugs Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Herpes Labialis Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Herpes Labialis Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Herpes Labialis Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Herpes Labialis Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Herpes Labialis Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Herpes Labialis Drugs Value Chain Analysis
- 8.1.1 Herpes Labialis Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Herpes Labialis Drugs Production Mode & Process
- 8.2 Herpes Labialis Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Herpes Labialis Drugs Distributors
- 8.2.3 Herpes Labialis Drugs Customers
9 Global Herpes Labialis Drugs Analyzing Market Dynamics
- 9.1 Herpes Labialis Drugs Industry Trends
- 9.2 Herpes Labialis Drugs Industry Drivers
- 9.3 Herpes Labialis Drugs Industry Opportunities and Challenges
- 9.4 Herpes Labialis Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst